Work

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

Year: 2025

Type: article

Abstract: Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus - 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable.

Source: AIDS Research and Therapy

DOI: 10.1186/s12981-025-00728-6

Authors: Hamed Mirmoezzi, Hamid Emadi Koochak, Seyed Ali Dehghan Manshadi, Malihe Hasannezhad, SeyedAhmad SeyedAlinaghi, Kiavash Semnani, Ladan Abbasian, Sara Ghaderkhani

Institutions: Tehran University of Medical Sciences, Imam Khomeini Hospital, Iranian Research Center for HIV/AIDS

Language: English

Subfield: Emergency Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,990

OpenAlex ID: W4408481577

FWCI:

Cites: 21

Cited by:

Related to: 10